Jpmorgan Chase & CO Ice Cure Medical Ltd. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Ice Cure Medical Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,950 shares of ICCM stock, worth $4,403. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,950
Previous 5,950
-0.0%
Holding current value
$4,403
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ICCM
# of Institutions
13Shares Held
100KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA25.6KShares$18,9140.0% of portfolio
-
Hrt Financial LP New York, NY18.7KShares$13,8570.0% of portfolio
-
Kingdom Financial Group Llc. Peoria, AZ15.3KShares$11,2850.01% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ15.3KShares$11,2850.0% of portfolio
-
Foundations Investment Advisors, LLC10KShares$7,4000.0% of portfolio
About IceCure Medical Ltd.
- Ticker ICCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 36,835,600
- Market Cap $27.3M
- Description
- IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.